AWM
XERS icon

Apollon Wealth Management’s Xeris Biopharma Holdings XERS Stock Holding History

Apollon Wealth Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,201
Closed -$113K – 1380
2025
Q2 		$113K Buy
24,201
+41
+0.2% +$188 ﹤0.01% 1215
2025
Q1 		$133K Buy
24,160
+4,000
+20% +$16.1K ﹤0.01% 1132
2024
Q4 		$68.3K Hold
20,160
– – ﹤0.01% 1155
2024
Q3 		$57.5K Hold
20,160
– – ﹤0.01% 1108
2024
Q2 		$45.4K Hold
20,160
– – ﹤0.01% 1074
2024
Q1 		$44.6K Sell
20,160
-9
-0% -$23 ﹤0.01% 1089
2023
Q4 		$47.4K Buy
20,169
+9
+0% +$17 ﹤0.01% 1051
2023
Q3 		$37.5K Hold
20,160
– – ﹤0.01% 890
2023
Q2 		$52.8K Hold
20,160
– – ﹤0.01% 921
2023
Q1 		$32.9K Hold
20,160
– – ﹤0.01% 851
2022
Q4 		$26.8K Hold
20,160
– – ﹤0.01% 837
2022
Q3 		$31K Hold
20,160
– – ﹤0.01% 789
2022
Q2 		$31K Hold
20,160
– – ﹤0.01% 735
2022
Q1 		$52K Hold
20,160
– – ﹤0.01% 736
2021
Q4 		$59K Hold
20,160
– – ﹤0.01% 744
2021
Q3 		$49K Buy
+20,160
New +$58.5K 0.01% 463
2021
Q2 		– Sell
-25,002
Closed -$113K – 385
2021
Q1 		$113K Buy
25,002
+692
+3% +$3.73K 0.02% 333
2020
Q4 		$120K Buy
+24,310
New +$122K 0.03% 193

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Apollon Wealth Management's XERS Position: Q3 2025 in Review

Apollon Wealth Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 24,201 shares — an estimated $113K sold.

Apollon Wealth Management first reported a position in XERS in Q4 2020 and held it in 18 quarters. The position peaked at $133K in Q1 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • Apollon Wealth Management reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Apollon Wealth Management sold 24,201 Xeris Biopharma Holdings shares in Q3 2025, an estimated $113K.
  • Apollon Wealth Management first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 18 quarters.
  • Apollon Wealth Management's Xeris Biopharma Holdings position peaked at $133K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Apollon Wealth Management's 13F filing for Q3 2025, filed 17 Oct 2025.